8 patents
Utility
Heterocyclic Compounds As Triggering Receptor Expressed on Myeloid Cells 2 Agonists and Methods of Use
21 Sep 23
Lara C. CZABANIUK, Timothy HOPPER, Jonathan B. HOUZE, Jane PANTELEEV, Gwenaella RESCOURIO, Vincent SANTORA, Haoxuan WANG, Ryan D. WHITE, Alice R. WONG, Yongwei WU, Maxence BOS, John MANCUSO, Ivan FRANZONI
Filed: 30 Nov 22
Utility
Heterocyclic Compounds As Triggering Receptor Expressed on Myeloid Cells 2 Agonists and Methods of Use
21 Sep 23
Lara C. CZABANIUK, Timothy Hopper, Jonathan B. Houze, Jane Panteleev, Gwenaella Rescourio, Vincent Santora, Haoxuan Wang, Ryan D. White, Alice R. Wong, Yongwei Wu, Maxence Bos, John Mancuso, Ivan Franzoni
Filed: 30 Nov 22
Utility
Heterocyclic compounds as triggering receptor expressed on myeloid cells2 agonists and methods of use
8 Aug 23
Lara C. Czabaniuk, Timothy Hopper, Jonathan B. Houze, Gwenaella Rescourio, Vincent Santora, Haoxuan Wang, Ryan D. White, Alice R. Wong, Yongwei Wu
Filed: 30 Nov 22
Utility
Heterocyclic Compounds As Triggering Receptor Expressed on Myeloid CELLS2 Agonists and Methods of Use
11 May 23
Lara C. CZABANIUK, Timothy HOPPER, Jonathan B. HOUZE, Gwenaella RESCOURIO, Vincent SANTORA, Haoxuan WANG, Ryan D. WHITE, Alice R. WONG, Yongwei WU
Filed: 30 Nov 22
Utility
Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
21 Mar 23
Lara C. Czabaniuk, Timothy Hopper, Jonathan B. Houze, Jane Panteleev, Gwenaella Rescourio, Vincent Santora, Haoxuan Wang, Ryan D. White, Alice R. Wong, Yongwei Wu, Maxence Bos, John Mancuso, Ivan Franzoni
Filed: 4 May 21
Utility
Treatment of Diseases Related to Atp-binding Cassette Transporter 1 Dysfunction Using TREM2 Agonists
16 Mar 23
The present invention provides a method of treating a disease or disorder caused by and/or associated with ABCD1 dysfunction in a human patient, the method comprising administering to the patient in need thereof an effective amount of a compound that increases the activity of triggering receptor expressed on myeloid cells 2 (TREM2).
Spyridon PAPAPETROPOULOS, Richard FISHER, Matthew BRENNAN
Filed: 6 Dec 21
Utility
Heterocyclic Compounds As Triggering Receptor Expressed on Myeloid Cells 2 Agonists and Methods of Use
5 Jan 23
Lara C. CZABANIUK, Timothy HOPPER, Jonathan B. HOUZE, Jane PANTELEEV, Gwenaella RESCOURIO, Vincent SANTORA, Haoxuan WANG, Ryan D. WHITE, Alice R. WONG, Yongwei WU, Maxence BOS, John MANCUSO, Ivan FRANZONI
Filed: 4 May 21
Utility
Treatment of Diseases Related to Colony-stimulating Factor 1 Receptor Dysfunction Using TREM2 Agonists
24 Mar 22
The present invention provides a method of treating a disease or disorder caused by and/or associated with CSF1R dysfunction in a human patient, the method comprising administering to the patient in need thereof an effective amount of a compound that increases the activity of triggering receptor expressed on myeloid cells 2 (TREM2).
Matthew BRENNAN, Judith Dunn, Richard Fisher, Berkley A. Lynch, Steven Robinette
Filed: 5 Aug 21
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first